Long-term safety of aromatase inhibitors in the treatment of breast cancer by Nabholtz, Jean-Marc A
© 2008 Dove Medical Press Limited.   All rights reserved
Therapeutics and Clinical Risk Management 2008:4(1) 189–204 189
REVIEW
Long-term safety of aromatase inhibitors 
in the treatment of breast cancer
Jean-Marc A Nabholtz
Breast Cancer Research Institute 
La Prandie, Valojoulx, France
Correspondence: Prof Jean-Marc Nabholtz
Breast Cancer Research Institute, 
La Prandie, 24290 Valojoulx, France
Tel +33 683 754470
Fax +33 553 510979
Email jmnabholtz@hotmail.com
Abstract: Following promising data for metastatic breast cancer in terms of efﬁ  cacy and safety 
proﬁ  le, third-generation aromatase inhibitors (AI), anastrozole, letrozole, and exemestane, under-
went a full development in early setting. If recent results consistently show the superiority of 
these agents over tamoxifen, the therapeutic strategies of AIs in adjuvant setting are still debated. 
Beyond the choice of clinical strategy, the long duration of exposure to AI in adjuvant setting 
required a full determination of the long-term toxicity proﬁ  le of these agents. While all three 
AIs have either favorable (decreased incidence of hot ﬂ  ashes, gynecologic and thromboembolic 
side-effects) or unfavorable (skeletal complications, arthralgia, musculoskeletal pain, sexual 
dysfunction) class adverse events, some variability between AIs has been reported in side-effects 
as well as gastrointestinal, urogenital, neurologic, and visual disturbances, conﬁ  rming the lack 
of interchangeability between the three AIs. The overall therapeutic index of AIs appears today 
superior to that of tamoxifen with proven improved efﬁ  cacy and better toxicity proﬁ  le. This 
review will explore the results from the available adjuvant AIs trials with a particular emphasis 
on safety proﬁ  les, quality of life, and therapeutic index, helping to deﬁ  ne the present role of AIs 
in the adjuvant management of postmenopausal patients with breast cancer.
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Introduction
Breast cancer is the most common cancer in women, with a worldwide yearly estimate 
of more than 1.1 million new cases of invasive breast cancer and more than 400,000 
deaths per year, in keeping with a high prevalence (more than 4.0 million survivors 
up to 5 years following diagnosis) (Parkin et al 2005). Early mammography screen-
ing programs and important therapeutic advances in the treatment of early (EBCTCG 
2005) and metastatic disease (André et al 2004) are thought to be the most important 
factors explaining this high prevalence.
In general, the treatment for patients with hormone-sensitive early breast cancer 
involves removal of the tumor by surgical and/or radiolotherapeutic techniques, fol-
lowed by adjuvant endocrine therapy. Most patients will be treated with endocrine 
therapy postoperatively, since the use of adjuvant therapy signiﬁ  cantly reduces the 
risks of tumor recurrence (EBCTCG 2005). In addition to endocrine therapies, adju-
vant treatment may include chemotherapy, which has also been shown to increase 
survival (EBCTCG 2005).
When considering breast cancer carcinogenesis and therapeutic targeting, estrogens 
and oestrogen receptors are among the most relevant prognostic and predictive factors 
(Colozza et al 2005). Lifetime cumulative exposure to oestrogen and elevated levels of 
plasma oestrogen are correlated with the risk of developing breast cancer (EHBCCG 
2002), and the oestrogen receptor (ER) is increasingly expressed as normal epithelium 
progresses to hyperplasia, hyperplasia with atypia, and ﬁ  nally ductal carcinoma in situ Therapeutics and Clinical Risk Management 2008:4(1) 190
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(Allred et al 2001). Therefore, antagonizing oestrogen is a 
logical approach to the treatment and prevention of breast 
cancer.
Over 100 years ago, Beatson removed the ovaries of 
a premenopausal woman with advanced breast cancer, 
achieving a treatment response of 42 months’ duration 
and demonstrating, for the ﬁ  rst time, the value of estrogen 
withdrawal in the management of breast cancer (Beatson 
1896). Contemporary endocrine therapy was introduced to 
the clinic over 30 years ago. Subsequent investigation has, 
in the main, concentrated on providing additional endocrine 
methods of depriving tumor cells of estrogen stimulation 
or targeting the estrogen receptor (ER). The selective oes-
trogen receptor modulator (SERM), tamoxifen, has been 
for many years the standard adjuvant endocrine treatment 
for postmenopausal women with ER+ve and/or PgR+ve 
disease. However, tamoxifen was shown to be associated 
with side-effects, sometimes potentially life-threatening, 
due to its partial oestrogen agonist activity; these side-
effects include an increased incidence of endometrial cancer 
(Wysowski et al 2002; EBCTCG 2005) and thromboem-
bolic events (Fisher et al 1996) with an incidence related to 
the drug exposure duration. The facts that many advanced 
ER+ve tumors fail to respond to tamoxifen, and those 
that do respond ultimately acquire tamoxifen resistance, 
pleaded in favor of alternative endocrine therapies (Ring 
and Dowsett 2004). All these observations for tamoxifen led 
to the search of new anti-hormonal agents with improved 
therapeutic ratios.
The ﬁ  rst two generations of aromatase inhibitors (AIs) 
were introduced in the treatment of metastatic disease but, 
mostly related to an unfavorable therapeutic index compared 
to tamoxifen, did not reach the adjuvant setting (Segalof et al 
1962). More recently, third-generation AIs (anastrozole, 
letrozole, and exemestane) showed, for postmenopausal 
women with advanced disease, superiority over other 
hormonal agents, including megestrol acetate and most 
importantly tamoxifen (Buzdar et al 2002). These three 
endocrine agents were subsequently studied extensively 
in early breast cancer. In this article, we will review the 
efﬁ  cacy and safety data of long-term use of AIs for the adju-
vant treatment of postmenopausal patients with endocrine 
sensitive breast cancer.
Mechanism of action and 
pharmacology
In postmenopausal women, the AIs block the P450 cyto-
chrome enzyme aromatase, responsible for the conversion 
of androgens to estrogens via a pathway which is the main 
source of oestrogen, consequently suppressing oestrogen 
levels. In postmenopausal population, estrogens are produced 
in the adrenal glands, the skin, the muscles, and the adipose 
tissue (Miller and Dixon 2002). Additionally, a majority 
of breast tumors demonstrate the presence of intra-tumor 
aromatase activity, a likely source of local oestrogen for the 
tumor cells (Bolufer et al 1992).
In contrast, for premenopausal women, AIs induce 
an increase in gonadotropin secretion secondary to the 
reduced negative feedback of oestrogen to the pituitary. The 
consequence is ovarian stimulation and a potential increase 
in ovarian size which may result in ovarian cysts, thereby 
conﬁ  rming the absence of indication of AI treatment in 
premenopausal patients.
AIs were ﬁ  rst developed as a non-surgical means to 
reduce estrogen production in patients with hormone-
responsive tumors. The ﬁ  rst-generation AI, aminoglutethi-
mide, an inhibitor of adrenal steroidogenesis, was studied 
almost 30 years ago. However, although signiﬁ  cantly sup-
pressing estrogen production, this agent was non-speciﬁ  c, 
altering as a consequence several intra-adrenal enzyme 
pathways, and producing sedative side-effects at the level of 
the central nervous system (Samojlik et al 1980; Perez and 
Borja 1992) Subsequently, so-called ‘second-generation’ 
AIs, such as 4-hydroxyandrostenedione (formestane) and 
fadrozole (CGS 16,949A), were found to be signiﬁ  cantly 
more potent and better tolerated than aminoglutethimide. 
However, they did not show any beneﬁ  t over tamoxifen 
(Wiseman and McTavish 1993).
Subsequently, in the late 1980s and early 1990s, research 
focused on developing agents with increased potency and 
higher selectivity. The identiﬁ  cation of two different mecha-
nisms of aromatase inhibition led to the development of two 
types of third-generation AIs. Type I aromatase inhibitors 
are androgen analogues, which interfere with the substrate-
binding site of the enzyme and blocking the enzymatic 
complex by producing an unbreakable covalent bond between 
the inhibitor and the enzyme protein (they are also called 
aromatase inactivators). Exemestane is the only aromatase 
inactivator available as endocrine therapy.
Nonsteroidal type II AIs block the electron transfer chain 
by the cytochrome P450 prosthetic group of the aromatase 
complex, acting as competitive inhibitors reversibly bound 
to the active enzymatic site. There are two type II AIs in 
clinical practice: anastrozole and letrozole.
Secondary to a good biodisponibility, all AIs used in the 
clinic are given orally, once daily. The time duration needed Therapeutics and Clinical Risk Management 2008:4(1) 191
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to reach maximal estrogen suppression ranges from 2 to 
7 days. The half-lives are quite different between the vari-
ous AIs: respectively 41 and 27 hours for anastrozole and 
exemestane but longer for letrozole (96 hours). A likely 
consequence is the plasma steady-state drug level of 7 days 
achieved for anastrozole and exemestane and of 60 days for 
letrozole (Buzdar et al 2002).
All three third-generation AIs effectively reduce estra-
diol (E2), estrone (E1), and estrone-sulfate (E1S) plasma 
levels. One prospective trial compared the plasma E1, E1S, 
and E2 suppression after 6 weeks of treatment with either 
anastrozole or letrozole in postmenopausal patients with 
advanced disease. Letrozole was shown to be a slightly more 
potent suppressor of plasma oestrogen levels and total body 
aromatization compared to anastrozole (Geisler et al 2002). 
The clinical signiﬁ  cance of this observation is so far unclear. 
There are to date no direct comparative studies involving 
exemestane. Additionally, some studies have suggested that 
AIs have the capability to reduce the production of intra-
tumoral estrogens (Buzdar et al 2002).
Clinical development of aromatase 
inhibitors
Advanced breast cancer: rationale 
for use in adjuvant setting
The superiority of third-generation AIs over megestrol 
acetate in second-line therapy of advanced breast cancer led 
to the decision to challenge tamoxifen in ﬁ  rst-line metastatic 
as well as adjuvant settings.
Two pivotal, large, randomized trials subsequently 
showed anastrozole to significantly improve time-to-
progression (TTP) compared to tamoxifen in postmenopausal 
women with HR+ve advanced breast cancer (10.7 months 
vs 6.4 months, p = 0.022) (Bonneterre et al 2000, 2001; 
Nabholtz et al 2000). A further combined analysis at a median 
follow-up of 44 months also showed that anastrozole was at 
least as effective as tamoxifen in terms of overall survival 
(Nabholtz et al 2003). Tolerability beneﬁ  ts were reported, 
with anastrozole having signiﬁ  cantly fewer thromboembolic 
events and a lower incidence of vaginal bleeding compared 
to tamoxifen. No difference was observed between the two 
treatment in terms of hot ﬂ  ushes, bone fractures, or pain.
In the same setting, letrozole was reported to be superior 
to tamoxifen in a large, randomized, double-blind trial with 
signiﬁ  cantly improved response rates and time-to-progression 
(9.4 months and 6 months, p = 0.0001) (Mouridsen et al 
2003). The tolerability proﬁ  le was also more favorable for 
letrozole with a decreased incidence of thromboembolic 
events. No difference was noted between the therapies in 
terms of hot ﬂ  ushes, arthralgias, or bone pain. However, 
there was a suggestion that letrozole may slightly increase 
the cholesterol plasma levels.
In another randomized phase III trial, exemestane showed 
signiﬁ  cant improvements compared to tamoxifen in terms 
of response rate (46% vs 31%, p   0.05), clinical beneﬁ  t 
(66% vs 49%, p   0.05), and time-to-progression (10 months 
vs 6 months, p   0.05) (Paridaens et al 2004). The safety 
proﬁ  le was also favorable for exemestane with fewer hot 
ﬂ  ushes and a suggestion that the steroidal AI may have no 
impact on the bone and lipid metabolisms.
Only one randomized open-label phase IIIb/IV trial 
has compared compared two AIs (letrozole vs anastrozole) 
in advanced breast cancer previously treated with an anti-
oestrogen (Rose et al 2003). The overall response rate 
(ORR) was signiﬁ  cantly higher with letrozole (19.1% vs 
12.3%, p = 0.013), but there was no difference between the 
treatment arms in terms of clinical beneﬁ  t and TTP. Both 
agents were well tolerated and there were no signiﬁ  cant dif-
ferences in safety proﬁ  les.
Aromatase inhibitors as adjuvant 
treatment for breast cancer
Results from the EBCTCG trialists panel conﬁ  rmed that, 
before the emergence of third-generation AIs, adjuvant 
tamoxifen for 5 years (only for hormonal receptor-positive 
disease) reduced the annual breast cancer death rate by 31%, 
irrespective of the use of chemotherapy, age, progesterone 
receptor status, or other tumor characteristics (EBCTCG 
2005). Five years’ duration of tamoxifen treatment was 
considered optimal, being signiﬁ  cantly more effective than 
10 years’ or 2 years’ and less. Moreover, two additional 
observations deserved to be mentioned:
1.  The risk of recurrence is high in the ﬁ  rst 5 years after 
a diagnosis of breast cancer, but with the highest peak 
within 2–3 years of diagnosis, independently of nodal 
status (Saphner et al 1996). This observation supports 
the upfront use of the most powerful new drugs (risk of 
early relapse)
2. For  ER+ve tumors, the annual breast cancer mortal-
ity rates are similar during years 0–4 and 5–14, with 
2/3 of deaths occuring between years 5 and 15. This 
observation is in favor of the potential increased dura-
tion of adjuvant endocrine therapies beyond 5 years, 
pending improved efﬁ  cacy and good long-term toxicity 
proﬁ  les. Additionally, caution should be exercised when Therapeutics and Clinical Risk Management 2008:4(1) 192
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interpreting overall survival data of adjuvant trials for 
endocrine sensitive breast cancers: longer median follow-
ups, such as 8–15 years, are needed to fully evaluate 
the real impact of new endocrine treatments on overall 
survival.
Four different strategies were developed with third-
generation AIs in adjuvant setting (see available results 
in Table 1):
1.  The upfront strategy: As noted above, it appears highly 
important for women to receive the most effective adju-
vant therapy at the ﬁ  rst opportunity in order to minimize 
the early risk of relapse. Various trials compared AIs 
to tamoxifen for 5 years: anastrozole in the ATAC trial 
(ATAC Trialists’ Group 2002, 2003, 2005), letrozole in 
the BIG 1–98 trial (Coates et al 2007), and exemestane 
in the TEAM trial (data not yet available). Anastrozole 
and letrozole were shown to be superior to tamoxifen in 
terms of disease-free survival, time to recurrence, time to 
distant recurrence, and incidence of controlateral breast 
cancer. Overall survival data are presently inconclusive, 
most likely because of short median follow-ups for sur-
vival (ATAC: 68 months and BIG 1-98: 51 months).
2.  The sequential strategy: It could be important to intro-
duce the most effective adjuvant therapy when the 
risk of tamoxifen resistance is the highest (after the 
2nd year). The BIG 1-98 trial is the only study with a 
4-arm design comparing the 5-year sequence of either 
tamoxifen followed by letrozole or the inverse (letrozole 
followed by tamoxifen) to either 5 years of tamoxifen 
or letrozole. To date, no prospective data are available 
comparing upfront AIs to a sequence of tamoxifen-AI. 
Results from the sequential part of the BIG 1-98 study 
with letrozole will be available in the future. These data 
are eagerly awaited as this is the only trial comparing 
5 years of AI with 2 sequential strategies (tamoxifen-
letrozole and letrozole-tamoxifen), which will resolve 
the conceptual debate ‘sequential tamoxifen-AI versus 
upfront AI’.
3.  Switch strategy: Switching to an AI after 2 or 3 years 
of tamoxifen for patients presently on tamoxifen (total 
of 5 years) has been evaluated with either exemestane: 
IES (Coombes et al 2004, 2007) or anastrozole: ITA trial 
(Boccardo et al 2005a, b) and ABCSG8/ARNO studies 
(Jakecz et al 2005a). The switch strategy has frequently 
been confounded with the sequential strategy. The 
difference between the two approaches lies in the fact 
that the switch trials censor patients who have relapsed 
during the ﬁ  rst 2–3 years on tamoxifen, thus selecting a 
subpopulation of patients with higher endocrine sensitivity 
(as we can assume that patients who relapse early might 
be the least sensitive to hormonetherapy). Sequence trials 
include all patients from the onset of adjuvant endocrine 
therapy and thus all patients relapsing on tamoxifen during 
the ﬁ  rst 2–3 years of treatment are included as events in 
the trial analysis without any selection from the standpoint 
of endocrine sensitivity. As a consequence it is fallacious 
to use switch trials to reach conclusions on sequential 
strategies. Switching from tamoxifen to exemestane or 
anastrozole was reported to signiﬁ  cantly improve disease-
free survival and time to distant recurrence compared to 
continuing tamoxifen. Additionally, improved survival 
data are presently emerging with both AIs.
4.  Extended hormonetherapy strategy: The duration of 
hormonal treatment in adjuvant situation is an old 
question, but remains a fundamental issue. Results 
from the EBCTG analysis (EBCTCG 2005) clearly 
demonstrated that 5 years of adjuvant tamoxifen therapy 
was better than shorter durations. However, data from 
the National Surgical Adjuvant Breast Project (NSABP) 
B-14 trial failed to demonstrate a positive impact of 
prolonged tamoxifen treatment (10 years vs 5 years). 
This was related not only to a worse toxicity proﬁ  le seen 
with prolonged tamoxifen, but also to decreased efﬁ  cacy, 
most likely related to the estrogen agonist effect seen 
with long-term use of tamoxifen (Fisher et al 2004).
Considering the facts that adjuvant tamoxifen induced a 
carry-over effect at 10 and 15 years even when the treatment 
was stopped early, and that there is a signiﬁ  cant incidence of 
endocrine-sensitive patients having late relapses after 5–15 
years (EBCTCG 2005), the third-generation AIs were con-
sidered good candidates for trying to optimize the duration 
of adjuvant therapy while potentially taking advantage of 
the sequential approach. This led to two trials, both evaluat-
ing the role of introducing an AI after 5 years of adjuvant 
tamoxifen: one with letrozole vs placebo, National Cancer 
Institute of Canada (NCIC) MA 17 (Goss et al 2003, 2005) 
and the other one with anastrozole ABCSG 6a (Jakecz 
et al 2005b; Schmid et al 2003). A third trial involving 
exemestane (NSABP B-33) was closed after publication 
of the results of the MA17 study (Table 1).
The AI prolonged trials with letrozole and anastrozole 
demonstrate the beneﬁ  t of extending hormonal therapy 
beyond 5 years of tamoxifen. These results raise the 
question of the duration of adjuvant hormonal therapy 
beyond 5 years as well as the potential role played in 
these trials by the sequencing tamoxifen-AI.Therapeutics and Clinical Risk Management 2008:4(1) 193
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The real questions beyond these all these results are: How 
long should we expose the patients to AIs in adjuvant setting? 
Should we go beyond 5 years? Should we start AI upfront and 
for how long? Beyond the decision making of using AIs and 
how to use them in adjuvant setting remains the choice of AI 
to use among the 3 agents available in the clinic. There is no 
direct comparison between the molecules in adjuvant setting 
and thus the decision to use either agent should be based upon 
their respective efﬁ  cacy and most importantly their respective 
toxicity proﬁ  les with maturity of data and availability of 
results in the various reviewed clinical strategies.
Toxicity proﬁ  le of aromatase 
inhibitors
It is critically important to prospectively assess the long 
term side-effect proﬁ  le of AIs, as these agents have entered 
the adjuvant setting while the present recommendation 
for the duration of adjuvant endocrine therapy is 5 years. 
Because of short median exposure to hormone therapy, 
safety reports acquired from advanced breast cancer trials 
are usually sketchy, underestimating the toxicity proﬁ  le of 
new endocrine agents. At best, they provide some guidance 
to prospectively design the assessment of adverse events 
in adjuvant studies. Getting long-term prospective toxicity 
information is critical to evaluate the therapeutic index for 
new hormone therapy such as AIs.
Overall, the rate of adverse events (AE) did not differ 
with anastrozole compared to tamoxifen in the ATAC 
trial (68 months median follow-up: respectively 93.9% vs 
94.6%, p = ns) while the rate of drug-related AE leading to 
withdrawal was lower for patients treated with anastrozole 
(6.5% vs 8.9%, p = 0.0005) (ATAC Trialists’ Group 2005). In 
the BIG 1-98 trial with median follow-up of 51 months, more 
AE were observed with letrozole compared to tamoxifen 
(93.6% vs 88.4%) (Coates et al 2007). No difference in AE 
was reported in the IES between exemestane and tamoxifen 
(median follow-up: 55 months; respectively 92.5% vs 92.6, 
p = ns) (Coombes et al 2007).
In the ATAC trial, the incidence of serious adverse events 
(SAE) was signiﬁ  cantly lower with anastrozole vs tamoxifen 
(33.3% vs 36%, p = 0.03) while drug-related SAEs were less 
frequently seen with anastrozole (4.7% vs 9.0%, p = 0.0001). Life-
threatening SAE were reported in similar proportion between 
letrozole and tamoxifen in the BIG 1-98 study (respectively 
4.6% vs 3.8%) as were Grade 3–4 AEs with exemestane versus 
tamoxifen in the IES (respectively 18.4% vs 17.6%).
When reviewing all side-effects induced by long-term use 
of AIs versus tamoxifen, a trend seems to emerge (Table 2). 
Table 1 AIs results from adjuvant trials
Studies  ATAC (ATAC  BIG 1-98  IES  ITA  ABCSG  MA-17  ABCSG 6a
 Trialists’  (ﬁ  rst part)  (Coombes  (Boccardo  ARNO (Jakecz  (Goss 2005)  (Jakecz
 group  2005)  (Coates  2007)  2007)  2005a)  2005a)    2005b)
Schedule  Upfront   Upfront   Switch:  Switch:  Switch:   Extended   Extended 
  TAM 5 years   TAM 5 years    TAM   TAM   TAM   HT:   HT: 
  vs   vs  vs   vs   vs   letrozole vs   anastrozole 
  anastrozole   letrozole  exemestane   anastrozole   anastrozole   placebo after   vs placebo 
  5 years   5 years  after 2–3   after 2–3   after 2–3   5 years of   after 5 years 
      years of TAM   years of TAM   years of TAM   TAM   of TAM
      – total of 5   – total of 5   – total of 5    
      years years years  
Nb  patients  6241 4922  4724  448  3224  5187 856
Median  68 months  51 months  55 months  36 months  28 months  30 months  60 months
follow-up
Disease-free A    T L    T E    T A    T A    T L    Placebo A    Placebo
survival HR  = 0.83   HR = 0.82  HR = 0.75  HR = 0.42  HR = 0.60  HR = 0.60  HR = 0.64
 p  = 0.005  p = 0.004  p = 0.0001  p = 0.0001  p = 0.0009  p = 0.002  p = 0.04
Time to  A   T   L   T   N/A  N/A  N/A  N/A  N/A
recurrence  HR 0.74  HR 0.78
 p  = 0.0002  p = 0.004
Overall NSD  NSD  E    T   NSD  A   T   NSD  NSD
survival     HR  = 0.83    HR = 0.71
     p  = 0.05    p = 0.038
Abbreviations: NSD, Not statistically different; N/A, not available; A, anastrozole; L, letrozole; E, exemestane.Therapeutics and Clinical Risk Management 2008:4(1) 194
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A ﬁ  rst series of side-effects appears to be speciﬁ  c and favorable 
to AIs (hot ﬂ  ushes, gynecologic side-effects and cardio-vascular 
events including thromboembolism), a second series speciﬁ  c to 
all AIs but favorable to tamoxifen (bone fractures/ osteoporosis 
and arthralgia), and a third series more speciﬁ  c to a given AI 
(lipid metabolism, cardiac, cerebrovascular, and others).
Class effects of AIs, favorable to AIs
Hot ﬂ  ushes and night sweats
Hot ﬂ  ushes are frequently observed in adjuvant studies with 
endocrine agents with a usually high incidence, independently 
of the type of hormone therapy used, including placebo. Con-
sequently, hot ﬂ  ushes were prospectively assessed in the main 
adjuvant trials with AIs. In the ATAC study, the rate of hot 
ﬂ  ushes was signiﬁ  cantly lower with anastrozole compared to 
tamoxifen (35.7% vs 40.9%, p   0.0001). The BIG 1–98 study 
found also a signiﬁ  cant improvement in favor of letrozole vs 
tamoxifen for hot ﬂ  ushes (respectively 32.8% vs 37.4%, p   
0.001) and night sweats (respectively 14.2% vs 17.0%, p = 
0.007). However, when compared to placebo in the MA 17 trial, 
patients on letrozole experienced more hot ﬂ  ushes (58% vs 54%, 
p = 0.003). In contrast, a higher incidence of hot ﬂ  ushes and 
menopausal symptoms was reported with exemestane compared 
to tamoxifen in the IES, although without reaching the level of 
statistical signiﬁ  cance (hot ﬂ  ushes: 42.4% vs 39.9%, p = 0.08; 
menopausal symptoms:47.8% vs 45.1%, p = 0.06).
Gynecologic (Table 3)
Tamoxifen is known to have an oestrogenic effect on healthy 
endometrial tissue with consequences such as endometrial 
proliferation and thickening. Long-term use of tamoxifen has 
previously been associated with an increased risk of polyp 
formation, vaginal bleeding, and increased incidence of 
endometrial cancer (Bissett et al 1994; EBCTCG 2005,). In 
contrast, AIs induce uterine atrophy and may decrease tamoxi-
fen-induced changes, secondary to a prior course of therapy.
As expected when compared to tamoxifen, AI therapy 
resulted in fewer gynecological AEs. In the ATAC trial, 
gynecologic events (including endometrial hyperplasia, endo-
metrial neoplasia, cervical neoplasia, and enlarged uterine 
ﬁ  broids) were less frequent with anastrozole compared to 
tamoxifen (3.0% vs 10.0%; p   0.0001). As well, a lower 
incidence of gynecologic SAEs was reported with exemestane 
versus tamoxifen in the IES (5.9% vs 9.0%; p = 0.0002).
When prospectively assessed, vaginal bleeding was sig-
niﬁ  cantly less frequent with anastrozole than tamoxifen in the 
ATAC study (5.4% vs 10.2%; p   0.0001), as with letrozole in 
the BIG 1–98 trial (3.8% vs 8.3%; p   0.0001) and exemestane 
in the IES (4.6% vs 6.5%; p   0.008). The ABCSG 8/ARNO 
95 trials reported the combined incidence of vaginal bleeding 
and discharge, showing no difference between anastrozole 
and tamoxifen (18% vs 17%; p = 0.93). However, these safety 
results should be viewed with caution in these combined trials 
as adverse events were not prespeciﬁ  ed in the ARNO 95 study 
protocol. Interestingly, when letrozole was compared to pla-
cebo in the MA17 trial, vaginal bleeding was more frequent in 
patients treated with the placebo, conﬁ  rming the uterine effect 
of letrozole (8.0% vs 6.0%; p = 0.005). One consequence of 
vaginal bleeding is to mandate further investigations to rule 
out endometrial hyperplasia or cancer. In the ATAC study, 
signiﬁ  cantly fewer patients on anastrozole underwent hyster-
ectomies compared with those treated with tamoxifen (1.3% vs 
5.1%; p   0.0001). In the IES, the rate of uterine dilatation and 
curettage was signiﬁ  cantly lower with exemestane compared to 
tamoxifen (0.6% vs 1.4%; p = 0.009) and signiﬁ  cantly fewer 
patients treated with exemestane were diagnosed with endo-
metrial hyperplasia (0.1% vs 1.0%; p   0.0001) and uterine 
polyps/ﬁ  broids (1.2% vs 3.2%; p   0.0001) compared to those 
on tamoxifen. Of note, in this trial, the rate of hysterectomy 
was similar between the two treatment groups.
Vaginal discharge is usually related to a postmenopausal 
deﬁ  cit in estrogen, vaginal atrophy, and alkalinity. In the 
ATAC trial, fewer patients on anastrozole experienced vaginal 
discharge compared to those treated with tamoxifen (3.5% 
vs 13.2%; p   0.0001). In addition vaginal moniliasis was 
more frequently diagnosed for patients on tamoxifen versus 
anastrozole (4% vs 1%; p   0.0001) (ATAC Trialists’ Group 
2006). Similarly, more patients on tamoxifen presented with 
Table 2 Summary of adverse events of aromatase inhibitors 
(AIs)
Class effect of AIs:
 •  Favorable to AIs
    ο Hot  ﬂ  ushes and night sweats
    ο Gynecologic  events
    ο Thromboembolic  disease
 •  Unfavorable to AIs
    ο Skeletal  complications
    ο  Arthralgia and musculoskeletal pain
    ο Sexual  dysfunction
Non-class effects of AIs, speciﬁ  c to given AIs:
  ο Lipid  metabolism
  ο Cardiac  events
  ο Cerebrovascular  events
  ο  Other adverse events
      ο Gastrointestinal
      ο Urogenital
      ο Neurologic
      ο Visual  disturbancesTherapeutics and Clinical Risk Management 2008:4(1) 195
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vaginal discharge compared to women treated with exemes-
tane in the IES (3.9% vs 2.8%; p   0.04).
It has been established that the long-term use of 
tamoxifen bears an increased risk of endometrial cancer 
(EBCTCG 2005). Results with AIs conﬁ  rm a decreased 
risk of endometrial cancer compared to tamoxifen. In the 
ATAC trial, 5 patients were diagnosed with endometrial 
cancers compared to 17 on tamoxifen (0.22% vs 0.76%; 
p = 0.02). Similar results were published with letrozole 
vs tamoxifen in the BIG 1–98 study (16 cases vs 4 cases; 
p   0.05). For the switch trials, the incidence of endometrial 
cancer in the IES was doubled with tamoxifen compared to 
exemestane but did not reached the statistical signiﬁ  cance 
(0.4% vs 0.2%, p = ns) while there was a trend for fewer 
endometrial cancers with anastrozole vs tamoxifen in the 
ABCSG8/ARNO95 combined studies (p = 0.069). Finally, 
when compared to placebo in the MA 17 trial, only 4 patients 
on letrozole were reported having an endometrial cancer 
compared to 11 on placebo (p = 0.12).
Thromboembolic disease (Table 4)
It is known that breast cancer patients may develop thromboem-
bolic complications when physiological antithrombotic systems 
are defective or when prothrombotic activities overcome the 
normal physiological antithrombotic mechanisms (Schmitt et al 
1999). Venous thromboembolism classically occurs in patients 
with clinically overt cancer and may develop at any stage of the 
disease (Agnelli 1997). Treatments such as chemotherapy and 
certain endocrine therapies have been shown to further compound 
the risk of thromboembolic complications. In breast cancer 
patients undergoing chemotherapy, the incidence of thrombosis 
has been reported to range from 1.3% (stages I-III) to 17.6% 
(stage IV), with the highest risk observed in postmenopausal 
patients (Levine 1997). Tamoxifen has also been associated with 
a small but signiﬁ  cant increased risk of venous thromboembo-
lism, which is further worsened by the addition of chemotherapy. 
This increase in thromboembolic disease seen with tamoxifen is 
considered to be a consequence of its partial oestrogen receptor-
agonist activity in certain tissues (Schmitt et al 1999).
Table 3 Gynecologic side effects in adjuvant randomized trials comparing aromatase inhibitors to tamoxifen or placebo in breast cancer
Study  ATAC Anastrozole  BIG 1–98 Letrozole  ABCSG8/ARNO95  IES Exemestane  MA 17 Letrozole
  vs tam  vs tam  Anastrozole vs  vs tam  vs Placebo
  (ATAC group 2005)  (Coates 2007)  tam (Jakecz 2005a)  (Coombes 2007)  (Goss 2005)
Median  68 months  51 months  55 months  36 months  28 months
follow-up
Median exposure  5 years  51 months  3 years  2–3 years  2 years
to AI
Gynecologic AEs  3% vs 10%  N/A  N/A  N/A  N/A
 p    0.0001
Gynecologic  N/A  N/A  N/A  5.9% vs 9.0%  N/A
SAEs       p  = 0.0002
Vaginal  5.4% vs 10.2%  3.8% vs 8.3%  18% vs 17%  4.6% vs 6.5%  6.0% vs 8.0% 
bleeding p    0.0001 p    0.0001 p  = 0.93b p  = 0.008a p  = 0.005
Hysterectomy  1% vs 5% p   0.0001 N/A  N/A  No  difference  N/A
Uterine dilatation/  N/A  N/A  N/A  0.6% vs 1.4%  N/A
Curettage       p  = 0.009
Endometrial  N/A  N/A  N/A  0.1% vs 1.0%  N/A
hyperplasia       p    0.0001
Uterine polyps/  N/A  N/A  N/A  1.2% vs 3.2%  N/A
ﬁ  broids        p   0.0001
Vaginal  3.5% vs 13.2%  N/A  N/A  2.8% vs 3.9%  N/A
discharge p    0.0001     p  = 0.04
Endometrial  5 vs 17  4 vs 16  N/A  0.2% vs 0.4%  4 vs 11
cancer p  = 0.02 p    0.05   p  = ns p  = 0.12
Vaginal  18.5% vs 9.1%  N/A  N/A  23.5% vs 26.3%  22% vs 19%
drynessa         p  = 0.016
Dyspareuniaa  17.3% vs 8.1%  N/A  N/A  14.9% vs 15%  N/A
Loss of libidoa  34% vs 26.1%  N/A  N/A  41.2% vs 45.4%  N/A
aQuality of life questionnaires.
bVaginal bleeding and discharge.
Abbreviations: N/A, Not available; AEs, adverse events; SAEs, serious adverse events.Therapeutics and Clinical Risk Management 2008:4(1) 196
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Third-generation AIs, however, are potent inhibitors 
of oestrogen synthesis and have all been shown to sig-
niﬁ  cantly reduce the risk of thromboembolism compared 
with tamoxifen treatment in postmenopausal women with 
breast cancer. Both upfront therapy trials (ATAC and BIG 
1–98) reported signiﬁ  cant decreases in the rate of throm-
boembolic complications with the AI compared to tamoxi-
fen (anastrozole: 3% vs 5%, p = 0.0004; letrozole: 2.3% 
vs 3.8%, p   0.001). As well, in switch trials (IES and 
ABCSG 8/ARNO 95), exemestane induced fewer thromboem-
bolic events compared to tamoxifen (1.2% vs 2.3%, p = 0.004) 
and there were fewer thromboses on anastrozole vs tamoxifen 
(p = 034), with a trend for fewer embolic events on anastrozole 
(p = 0.064). Lastly, when comparing letrozole to placebo in the 
MA 17 study, there was no signiﬁ  cant difference in terms of 
thromboembolic events between the two patient groups.
Class effects of AIs, favorable 
to tamoxifen
Skeletal complications (Table 5)
Tamoxifen is known to have a positive effect on bone mineral 
density in postmenopausal breast cancer patients (Powles 
et al 1996), but to date, tamoxifen has not been evaluated in 
a prospective trial in women with osteoporosis.
Patients treated in all the adjuvant large-scale randomized 
trials with anastrozole, letrozole, or exemestane clearly had 
an increasing rate of skeletal disorders, particularly osteo-
porosis and bone fractures, even in trials in which they were 
compared to placebo.
In the ATAC trial, anastrozole was associated with a sig-
niﬁ  cant increased incidence of fractures compared to tamoxi-
fen (11.0% vs 7.7%, p   0.0001). While the incidences of 
hip fractures (fracture type associated with high morbidity 
and mortality) and wrist fractures were similar for anastro-
zole and tamoxifen (respectively, 1.2% vs 1.0%, p = 0.5 and 
2.3% vs 2.0%, p = 0.4), the difference was signiﬁ  cant in favor 
of tamoxifen for spinal fractures (1.5% vs 0.9%, p = 0.03) 
and all other sites of fractures (7.1% vs 4.6%, p   0.0001). 
Interestingly, the yearly fracture rate on anastrozole increased 
sharply compared to tamoxifen during the ﬁ  rst 2 years of 
therapy before stabilizing, with a relative risk of fracture 
remaining constant with longer duration of treatment (ATAC 
Trialists’ Group 2006). Finally at completion of therapy, the 
fracture rate reversed back to the lower rate observed with 
Table 4 Cardiovascular side effects in adjuvant randomized trials comparing aromatase inhibitors to tamoxifen or placebo in breast 
cancer
Study  ATAC   BIG 1–98   ABCSG8/ARNO95  IES   MA 17 
  Anastrozole   Letrozole   Anastrozole   Exemestane  Letrozole vs
  vs tam   vs tam   vs tam   vs tam  Placebo 
  (ATAC group  (Coates 2007)  (Jakecz 2005a)  (Coombes 2007)  (Goss 2005)
 2005)
Median follow-up  68 months  51 months  55 months  36 months  28 months
Median exposure to AI  5 years  51 months  3 years  2–3 years  2 years
All cardiac events  N/A  5.5% vs 5.0   N/A  16.5% vs 15.0%   5.8% vs 5.6% 
   8.3%      p  = 0.16a p  = 0.76
   P  = 0.48
•  Cardiac  N/A  74 pts vs 35  N/A  N/A  N/A
 events    pts
 Grade  3–5    p  = 0.05
Ischemic cardio-  4.1% vs 3.4%   2.2% vs 1.7%   N/A  8.0% vs 6.9%   N/A
vascular disease  p = 0.10 p  = 0.21   p  = 0.08
•  Angina  2.0% vs 1.5%  N/A  N/A  N/A  1.2% vs 0.9%
   p  = 0.07       p  = ns
•  Myocardial  1.0% vs 1.0%   N/A   1.0% vs  1.0%  1.3% vs 0.8%   0.3% vs 0.4% 
 infaction  p  = 0.5   p  = 1.0 p  = 0.08 p  = ns
•  Grade 3–5  N/A  42 pts vs 21  N/A  N/A  N/A
     pts  p  = 0.05
CVA/TIA  2.0% vs 3.0%   1.4% vs 1.4%   N/A  2.5% vs 2.4%   0.7% vs 0.6%
 p  = 0.03 p  = 0.90   p  = 0.89 p  = ns
Thromboembolic  3.0% vs 5.0%   2.0% vs 3.8%   Fewer on anastrozole   1.2% vs 2.3%   0.4% vs 0.2%
disease p  = 0.0004 p  = 0.001 p  = 0.034 p  = 0.004 p  = ns
aVaginal bleeding and discharge.
Abbreviations: N/A, not available; ns, not signiﬁ  cant; CVA/TIA, cerebro-vascular accident/transient ischemic attack.Therapeutics and Clinical Risk Management 2008:4(1) 197
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tamoxifen (Locker and Eastell 2003). As expected, in the 
ABCSG/ARNO trial, there were signiﬁ  cantly more fractures 
in patients switching to anastrozole versus those continuing 
on tamoxifen (2.4% vs 1.2%, p = 0.015).
Letrozole also bears an increased risk of fractures on the 
head-to-head comparison with tamoxifen (8.6% vs 5.8%, 
p   0.001) (Coates et al 2007). A more detailed analysis of 
osteoporosis and bone fractures was published for the MA17 
trial exploring the impact of extending treatment with letro-
zole compared to placebo (Goss et al 2005). More patients 
receiving letrozole had a new diagnosis of self-reported 
osteoporosis (8.1% vs 6.0%, p = 0.003) with a median time 
to occurrence of 0.70 years for those receiving letrozole 
and 0.52 years for those receiving placebo. Of a total of 256 
patients who experienced a clinical fracture during the study 
period, 137 (5.3%) were taking letrozole and 119 (4.6%) were 
on placebo (p = 0.25). The median time to fracture was 1.06 
year letrozole and 0.86 year for the placebo.
Even if preclinical data suggested that exemestane may yield 
a protective effect on bone metabolism, IES reported an increased 
incidence of osteoporosis with exemestane compared to tamoxi-
fen (7.3% vs 5.5%, p = 0.01). Similarly, bone fractures were more 
frequent in the exemestane group compared to the tamoxifen 
group (4.3% vs 3.1%, p = 0.03) (Coombes et al 2007).
Despite these results, there is today no skeletal contrain-
dication to the use of AIs in adjuvant setting. However, it is 
strongly recommended for patients, in particular for those 
with risk factors of osteoporosis, to determine the bone min-
eral density (BMD) status and the phosphocalcic metabolism, 
before initiating an AI therapy (Winer et al 2005). In case of 
normal upfront BMD, it is advised to proceed with another 
test at completion of adjuvant treatment with AI. In case of 
upfront osteopenia, another BMD should be performed after 
1–2 years on AI therapy. Finally, an upfront osteoporotic 
result should lead to the possible use of bisphosphonates 
concomitantly with the AI following promising preliminary 
reports showing a positive impact of bisphosphonates on the 
prevention of osteoporosis (Gnant et al 2004).
Arthralgia and musculoskeletal pain (Table 5)
In clinical practice, the main symptomatic issue with AIs 
remains arthralgias and ﬁ  bromyalgias for which no clear 
physiopathological explanation is known and no speciﬁ  c treat-
ment deﬁ  ned. Their assessment in the various adjuvant trials 
with AIs has been complex, mostly because of a lack of clear 
deﬁ  nition (arthralgia, arthritis, osteoarthritis, myalgia, muscle 
cramps, ﬁ  bromyalgia, bone pain, musculoskeletal pain).
In the ATAC trial, arthralgia was a predeﬁ  ned adverse 
event and was recorded as a grouping of arthralgia, arthritis, 
arthrosis, and joint disorders (Buzdar et al 2006). Signiﬁ  -
cantly more patients treated with anastrozole presented with 
arthralgia compared to those on tamoxifen (35.6% vs 29.4%, 
p   0.0001). The median time to ﬁ  rst event was 13.9 months 
for anastrozole and 17.7 months for tamoxifen. Serious events 
were noted in similar proportions between the two treatment 
groups (10.6% for anastrozole and 10.4% for tamoxifen). 
Few patients from either group withdrew from treatment 
because of arthralgia (13 vs 6). More than 50% of patients 
with joint symptoms received treatment for pain manage-
ment. More than 90% of these patients were managed with 
nonsteroidal anti-inﬂ  ammatory drugs alone or in combina-
tion with other mild analgesics. As nonpre-speciﬁ  ed adverse 
events, muscle cramps were more frequent with tamoxifen 
than anastrozole (8% vs 4%, p   0.0001) while carpal tunnel 
syndrome was observed more with anastrozole (3% vs 1%, 
p   0.0001). In the switch portion of the Austrian ABCSG 8 
trial, bone pain was more frequent with anastrozole compared 
to tamoxifen (p = 0.054).
Table 5 Fractures and arthralgia in adjuvant randomized trials comparing aromatase inhibitors to tamoxifen or placebo in breast 
cancer
Study  ATAC Anastrozole  BIG 1–98 Letrozole  ABCSG8/ARNO95  IES Exemestane  MA 17 Letrozole 
  vs tam  vs tam  Anastrozole vs  vs tam  vs Placebo
  (ATAC group 2005)  (Coates 2007)  tam (Jakecz 2005a)  (Coombes 2007)  (Goss 2005)
Median follow-up  68 months  51 months  55 months  36 months  28 months
Median exposure  5 years  51 months  3 years  2–3 years  2 years
to AI
Fractures  11.0% vs 7.7%a 8.6%  vs  5.8%a  2.0% vs 1.0%b  4.3% vs 3.1%b  5.3% vs 4.6%b 
 p    0.0001 p    0.001 p  = 0.015 p  = 0.03 p  = 0.25
Arthalgia 35.6%  vs  29.4%a  8.3% vs 3.8%b  N/A  18.6% vs 11.8%b  25.0% vs 21.0%b 
 p    0.0001 p    0.0001   p    0 .0001  p   0.001
aPrespeciﬁ  ed.
bNot prespeciﬁ  ed.
Abbreviation: N/A, not available.Therapeutics and Clinical Risk Management 2008:4(1) 198
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Arthralgia and myalgia were not prespeciﬁ  ed in the 
BIG 1–98 trial, but were part of an ‘other’ category and 
thus could be underestimated. Nevertheless, letrozole 
induced more arthralgia than tamoxifen (20.0% vs 13.5%, 
p   0.001). When looking at the grading according to 
the National Cancer Institute Common Toxicity Criteria 
(version 2.0), the great majority of patients with arthralgia 
in the letrozole arm suffered grade 1–2 (444 pts of 489, 
90.8%) with only 43 cases of grade 3 (8.8%) and 2 cases 
of grade 4 (0.4%). There was no signiﬁ  cant difference in 
terms of myalgia between the 2 treatment groups (p = 0.19). 
Interestingly, the MA 17 trial comparing letrozole to pla-
cebo found more patients with myalgias in the letrozole 
arm (15% vs 12%, p = 0.004) while bone pain was recorded 
in comparable proportion of cases between the 2 arms 
(letrozole: 5% vs placebo:6%, p = 0.67). Nevertheless, 
arthralgias were more frequent with letrozole compared 
to placebo (25% vs 21%, p   0.001).
In the switch IES, there was a higher frequency of 
arthralgia in the exemestane group compared to tamoxifen 
(18.6% vs 11.8%, p   0.0001). The incidence of arthri-
tis was also higher with exemestane (14.1% vs 12.0%, 
p   0.03) while osteoarthritis was reported in similar 
proportion between the two treatment groups (8.7% vs 
7.4%, p = 0.113). Carpal tunnel syndrome was more fre-
quent on exemestane versus tamoxifen (2.8% vs 0.0%, 
p   0.0001). Finally, musculoskeletal pain was observed 
in 21% of patients on exemestane versus 16% for those on 
tamoxifen (p   0.0001).
Sexual dysfunction (Table 3)
Sexual dysfunction is a frequent event for patients treated 
with endocrine therapy, although potentially under-reported 
in breast cancer studies. Sexual dysfunction was usually 
assessed in the various adjuvant trials with AIs either as non 
predeﬁ  ned adverse events (vaginal dryness, dyspareunia, 
loss of libido) or as part of quality of life (QoL) modules 
(Whelan et al 2005; Cella et al 2006; Fallowﬁ  eld et al 2006). 
Secondary to low estrogen levels, vaginal dryness can induce 
dyspareunia as well as decreased libido. As expected, vaginal 
dryness was more frequently seen with AIs compared to 
tamoxifen in the ATAC and MA 17 trials. More patients on 
anastrozole than tamoxifen reported dyspareunia (28 vs 9, 
p = 0.002) and decreased libido (39 vs 12, p = 0.0001) (Cella 
et al 2006). Quality of life studies in the MA 17 trial showed a 
signiﬁ  cant worsening of the parameters of the sexual domain 
with letrozole compared to placebo (Whelan et al 2005). As 
well, sexual dysfunction was also observed with exemestane 
in the IES, but without reaching the statistical signiﬁ  cance 
when compared to tamoxifen (Fallowﬁ  eld et al 2006).
Side effects speciﬁ  c to given AIs
Lipid metabolism
Postmenopausal women are known to have increased levels 
of low-density lipoprotein cholesterol (LDL-C) and decreased 
levels of high-density lipoprotein cholesterol (HDL-C) com-
pared to premenopausal women of the same age, and these 
unfavorable changes are considered to be a risk factor for 
the development of coronary heart disease (Gorodeski 2002). 
There is no clear evidence that tamoxifen favorably inﬂ  u-
ences the lipid metabolism especially when considering the 
results from the Women’s Health Initiative study (Rossouw 
et al 2002). It is, therefore, important to ascertain whether 
or not long-term treatment with anastrozole, letrozole, or 
exemestane has an impact on the lipid parameters.
Anastrozole was ﬁ  rst assessed in advanced breast can-
cer studies in a combined analysis of the North American 
and Tamoxifen or Arimidex Randomized Group Efﬁ  cacy 
and Tolerability (TARGET) trials. This study on 600 post-
menopausal patients concluded that neither anastrozole nor 
tamoxifen had a clinically signiﬁ  cant impact on total choles-
terol (Dewar et al 2000). Other studies in metastatic breast 
cancer, consistent with this analysis, showed no signiﬁ  cant 
change in total cholesterol, LDL-C, HDL-C, or triglycer-
ides. Furthermore, there was no change in the atherogenic 
risk ratios of total cholesterol/HDL-C and LDL-C/HDL-C 
(Wojtacki et al 2004).
In early breast cancer, a small study evaluated the effects 
of anastrozole on lipid proﬁ  les of 54 postmenopausal women. 
Anastrozole induced no signiﬁ  cant change of serum levels 
of apolipoprotein A1, apolipoprotein B, triglycerides, total 
cholesterol, HDL-C, and LDL-C. Atherogenic risk ratios 
(total cholesterol/HDL-C, LDL-C/HDL-C and apolipopro-
tein A1/apolipoprotein B) were stable from baseline to vari-
ous measurements at 1, 3, 6, and 12 months (Wojtacki et al 
2005). Additionally, potential changes in serum lipid proﬁ  les 
were investigated in a neoadjuvant randomized trial (n = 176) 
comparing anastrozole or tamoxifen alone or in combina-
tion. Treatment with either tamoxifen or anastrozole for 12 
weeks was associated with a signiﬁ  cant increase of HDL-C 
levels in both groups, whereas total cholesterol decreased in 
the tamoxifen group and increased in the anastrozole group, 
although not signiﬁ  cantly (Banerjee et al 2005). Following 
these results with anastrozole on lipid parameters in advanced 
breast cancer, serum lipid levels were not prospectively stud-
ied in the ATAC trial. Hypercholesterolemia was assessed Therapeutics and Clinical Risk Management 2008:4(1) 199
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as a nonpre-deﬁ  ned adverse event and results showed an 
increased incidence with anastrozole versus tamoxifen in 
the ‘completion of 5 years’ treatment analysis’ (9% vs 3%, 
p   0.0001) (ATAC Trialists’ Group 2006).
The impact of letrozole on lipid composition was initially 
measured in a small study of 20 postmenopausal women 
with advanced breast cancer. Results showed a signiﬁ  cant 
increase in total cholesterol (p  0.05), LDL-C (p   0.01) and 
apolipoprotein B levels (p = 0.05) after 16 weeks of treat-
ment. In addition, there was evidence of unfavorable changes 
in the atherogenic risk ratios of total cholesterol/HDL-C 
(p   0.005), LDL-C/HDL-C (p   0.005) and apolipoprotein 
A1/apolipoprotein B (p = 0.005) (Elisaf et al 2001). Conse-
quently, hypercholesterolemia was prospectively studied in 
the BIG 1–98 trial. Results showed a signiﬁ  cantly higher 
prevalence for hypercholesterolemia in patients treated with 
letrozole versus those receiving tamoxifen (respectively 
50.6% vs 24.6%, p   0.001). However, the great majority 
(99%) of these cases of hypercholesterolemia were graded 
1 or 2 (Coates 2007). In contrast, the MA.17 lipid substudy 
showed no signiﬁ  cant changes induced by letrozole on cho-
lesterol (including LDL or HDL fractions) (16% vs 16%, 
p = 0.79), triglycerides or lipoprotein over a period of treatment 
of 3 years following 5 years of tamoxifen (Wasan 2005).
Exemestane was ﬁ  rst evaluated in a 9-week study, in which 
plasma changes in advanced breast cancer patients demon-
strated a signiﬁ  cant decrease in total cholesterol (p   0.01), 
triglycerides (p = 0.023) and apolipoprotein A1 (p   0.01). 
Additionally, there was also a signiﬁ  cant decrease in HDL-C 
(p   0.01) and in the apolipoprotein A1/apolipoprotein B 
atherogenic risk ratio (p   0.01) (Engan et al 1995).
In contrast, a substudy of an advanced breast cancer phase 
II randomized trial did not ﬁ  nd the treatment with either 
exemestane or tamoxifen to have a signiﬁ  cant effect on total 
cholesterol, HDL-C, apolipoprotein A1, or apolipoprotein 
B. However, at week 24, exemestane was associated with a 
signiﬁ  cant increase in triglycerides (p = 0.002) (Atalay et al 
2004). In the IES, there was no difference in hypercholester-
olemia levels between patients on exemestane versus those 
treated with continued tamoxifen (7.2% vs 6.0%, p = 0.12) 
(Coombes et al 2007).
In terms of comparative studies between the AIs, an early 
breast cancer study compared the effects of adjuvant exemes-
tane and anastrozole on serum lipids in postmenopausal 
women (Kataja et al 2002). After 12 weeks of treatment, 
exemestane and anastrozole had no clinically signiﬁ  cant 
impact on total cholesterol, HDL-C, LDL-C or triglycerides 
compared with baseline. Anastrozole did, however, show 
an increase in HDL-C levels whereas exemestane showed a 
decreased HDL-C levels. A second small randomized study, 
the Letrozole, Exemestane, and Anastrozole Pharmacodynam-
ics trial (LEAP) compared the lipid proﬁ  les of 90 evaluable 
healthy volunteers, receiving either anastrozole (1 mg/day), 
letrozole (2.5 mg/day) or exemestane (25 mg/day) once 
daily for 24 weeks (McCloskey 2005). Results showed no 
signiﬁ  cant changes of lipid parameters for women exposed 
to anastrozole. while letrozole induced a signiﬁ  cant increase 
in triglycerides levels without effect on the atherogenic ratios. 
Exposure to exemestane resulted in a signiﬁ  cant increase of 
the atherogenic ratios LDL-C/HDL-C and apolipoprotein B/
apolipoprotein A1, compared to anastrozole and letrozole.
The molecular differences between anastrozole, letro-
zole, and exemestane, therefore, could not only affect the 
selectivity for the aromatase complex with small differences 
in plasma oestrogen suppression, but could also play a role 
in the small variations in lipid alterations induced by the 
third-generation AIs. Although these differences between the 
AIs may not signiﬁ  cantly inﬂ  uence the clinical efﬁ  cacy, it is 
unknown so far whether or not these modiﬁ  ed lipid proﬁ  les 
may translate into a long-term increased risk of cardiovas-
cular (CV) disease.
Cardiac adverse events (Table 4)
No cardiac safety issues were identiﬁ  ed for any of the AIs in 
the advanced breast cancer setting. However, the duration of 
exposure to the drugs was relatively short and CV events were 
not a particular focus of safety analyses in these metastatic 
trials (Nabholtz and Glogorov 2006).
In the last analysis of the ATAC trial (68 months median 
follow-up), the incidence of ischemic cardiac disease was 
comparable for patients treated with anastrozole compared 
with those on tamoxifen (4.1% vs 3.4%, p = 0.10) (ATAC 
Trialists’ Group 2005). There was a numerical increase, 
although not statistically signiﬁ  cant, in terms of angina with 
anastrozole compared to tamoxifen (71 cases vs 51 cases, 
p = 0.07). However, this was not considered to be a safety 
concern, as there was no correlation with prolonged treat-
ment, and the majority of events were mild to moderate in 
severity. Additionally, there was no difference in myocardial 
infarctions between anastrozole and tamoxifen at 68 months 
(37 cases vs 34 cases, p = 0.7) (ATAC Trialists’ Group 2006) 
while the number of CV deaths was similar in the two treat-
ment groups (49 vs 46, respectively).
In keeping with these data, no difference in myocardial 
infarctions were observed in the ABCSG 8/ARNO 95 trials 
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continuing tamoxifen (2 cases vs 3 cases). Available CV 
data from the ITA trial are limited to the incidence of CV 
disease, which showed no signiﬁ  cant difference between the 
tamoxifen group and the anastrozole group (9.3% and 7.9%, 
respectively; p = 0.4) (Boccardo et al 2005b).
The recent updated analysis of the BIG 1–98 trial, at 
51 months median follow-up, reported no signiﬁ  cant difference 
in incidence of any grade cardiac events between letrozole 
and tamoxifen (5.5% vs 5.0%, p = 0.48) (Coates 2007). 
However, patients on letrozole experienced a signiﬁ  cantly 
greater incidence of grade 3–5 cardiac events than those on 
tamoxifen (74 cases vs 35 cases, p   0.05). These events 
consisted mostly of ischiemic heart disease (42 cases vs 21 
cases, p   0.05) and cardiac failures (24 cases vs 14 cases). 
Cardiac deaths were reported in 11 cases on letrozole and 5 
on tamoxifen. Of particular interest is the fact that there was 
no clear evidence of correlation between cardiac deaths and 
the statistically signiﬁ  cant increased number of hypercholes-
terolemia in the letrozole arm. Clearly, these results should 
be put in the context of the total number of deaths without 
cancer event (letrozole: 60 vs tamoxifen: 48) and the total 
number of deaths in the trial (letrozole: 194 vs tamoxifen:211, 
p = ns) (Coates et al 2007).
Cardiovascular data from the MA17 (letrozole arm: 2593 
patients and placebo arm: 2394 patients) showed no overall 
signiﬁ  cant difference between letrozole and placebo in terms 
of CV disease (respectively 5.8% and 5.6%, p = 0.76), includ-
ing myocardial infarction and new or worsening angina.
In the IES at 55 months’ median follow-up, there was 
no signiﬁ  cant difference in the overall incidence of CV 
events (excluding thromboembolism) between the two 
treatment arms (exemestane: 16.5% vs tamoxifen: 15.0%, 
p = 0.16) (Coombes et al 2007). The incidence of ischiemic 
cardiovascular disease was comparable between the 2 arms 
(exemestane: 8.0% vs tamoxifen: 6.9%, p = 0.17) and, in 
contrast with preliminary reports, there was no statistically 
signiﬁ  cant difference in terms of myocardial infarctions 
between patients on exemestane and those on tamoxifen 
(respectively 31 cases vs 19 cases, p = 0.08). Of particular 
note is the fact that 22 patients on exemestane (71%) had 
a prior history of high blood pressure compared to only 6 
patients on tamoxifen. The number of deaths due to cardiac 
causes was very low in both arms.
Cerebrovascular adverse events (Table 4)
Consistent with the initial analyses of the ATAC study, 
ischemic cerebrovascular adverse events at 68 months were 
signiﬁ  cantly reduced for patients treated with anastrozole 
compared with those treated with tamoxifen (62 cases/2% vs 
88 cases/3%, p = 0.03). This translated in 14 cerebrovascular 
deaths on anatrozole vs 22 on tamoxifen (p = ns).
None of the other adjuvant trials, with letrozole and 
exemestane, showed any evidence of decreased cerebro-
vacular events compared to tamoxifen or placebo. In the 
BIG 1–98 trial, there was no difference in the incidence of 
cerebrovascular adverse events/transient ischemic attack 
between letrozole and tamoxifen (1.4% vs 1.4%, p = 0.90). A 
total of 7 cerebrovascular deaths were reported, 4 on letrozole 
and 3 on tamoxifen. As well, the MA 17 showed a similar 
rate of cerebrovascular adverse events between letrozole and 
placebo (0.7% vs 0.6%, p = ns). Lastly, these events occurred 
in similar proportion between exemestane and tamoxifen in 
the IES (2.5% vs 2.4%, p = 0.89).
Other adverse events (Table 2)
The gastrointestinal toxicity of AIs is usually mild with 
no evidence of increased nausea/vomiting compared to 
tamoxifen or placebo. However, diarrhea appeared to be 
signiﬁ  cantly more frequent with exemestane compared to 
tamoxifen in the IES (4.2% vs 2.2%, p   0.0001) and with 
anastrozole in the ATAC trial (9% vs 7%, p = 0.02). However, 
no difference in diarrhea was noted between anastrozole and 
tamoxifen in the ABCSG 8/ARNO 95 study and between 
letrozole and placebo in the MA 17 trial.
Urogenital side-effects were only reported in the ATAC 
trial with a signiﬁ  cant decreased incidence of urinary 
incontinence with anastrozole compared to tamoxifen 
(2.0% vs 4.0%, p   0.0001) and less urinary tract infec-
tions for patients on the AI versus tamoxifen (8% vs 10%, 
p = 0.002).
Mild neurologic toxicity was recorded with anastrozole 
in the ATAC study consisting of paresthesia seen more 
frequently than with tamoxifen (7% vs 5%, p = 0.0001). 
Exemestane, as well, induced an increased incidence of 
paresthesia compared to tamoxifen in the IES (2.8% vs 
1.0%, p   0.0001).
High blood pressure was more frequent with anastrozole vs 
tamoxifen in the ATAC trial (13% vs 11%, p = 0.04) and with 
exemestane in the IES (35.8% vs 33.0%, p = 0.05). The MA 
17 showed no difference between letrozole and placebo.
In terms of visual disturbances, there was no differ-
ence in the ATAC trial for cataracts (prespeciﬁ  ed AE) 
between anastrozole and tamoxifen. Visual disturbances 
(unspeciﬁ  ed types) were reported to be more frequent with 
exemestane vs tamoxifen in the preliminary analysis of IES 
at 30.7 months median follow-up (7.4% vs 5.7%, p  0.05)Therapeutics and Clinical Risk Management 2008:4(1) 201
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(Coombes et al 2004). However, there was no update on 
visual toxicity in the recent publication at median follow-up 
of 55 months (Coombes et al 2007).
Quality of life with of aromatase 
inhibitors
When considering the role of new endocrine therapy in 
early breast cancer, efﬁ  cacy and safety with in particular the 
impact on quality of life (QoL) are today critical for decision 
making in the clinic.
In the ATAC trial, using the validated instrument Func-
tional Assessment of Cancer Therapy – Breast plus Endo-
crine Subscale (FACT-B + ES) and despite different toxicity 
proﬁ  les recorded at 5 years median follow-up, no difference 
between anastrozole and tamoxifen were observed in terms 
of Trial Outcome Index (TOI) and its physical and functional 
components (Cella et al 2006). However, after an initial 
worsening of the TOI at 3 months follow-up, both treatments 
showed, compared to baseline, improvements in QoL over 
the rest of the 5-year period.
The impact on QoL of letrozole compared with placebo 
after 5 years of adjuvant tamoxifen was evaluated in the 
MA.17 trial, using the validated Short Form 36-item Health 
Survey (SF-36) and Menopause Speciﬁ  c Quality of Life 
(MENQOL) questionnaires (Whelan et al 2005). Published 
quality-of-life analysis for this study found no global dif-
ferences between treatment groups in mean change scores 
from baseline for the SF-36 physical and mental component 
summary scores. On the response analysis, a signiﬁ  cant dif-
ference in favor of placebo was seen between groups for the 
bodily pain domain (p = 0.009) and the vasomotor domain 
(p = 0.001) (Whelan et al 2005).
Exemestane was assessed, compared to tamoxifen, in the 
IES with the FACT-B instrument (Fallowﬁ  eld et al 2006). 
There was no signiﬁ  cant difference between the two treat-
ment drugs in terms of TOI and its physical and functional 
components over a period of 2 years. Additionally, the mean 
endocrine subscale scores increased compared to baseline for 
both exemestane and tamoxifen.
Clinical issues from long-term 
toxicity proﬁ  les of AIs
Third-generation AIs have produced signiﬁ  cant improve-
ments in the treatment of early breast cancer for postmeno-
pausal women. These agents have shown superiority over 
tamoxifen in both the initial adjuvant and switch settings 
and have induced improved outcome compared to placebo 
in the extended hormone therapy setting beyond 5 years of 
tamoxifen. Despite no head-to-head trials comparing AIs 
in adjuvant setting, efﬁ  cacy data for these agents may be 
relatively comparable in the different settings in which they 
were studied. However, in terms of safety proﬁ  les, results of 
adjuvant studies suggest that there may be some differences 
between these agents, conﬁ  rming that today AIs should not 
be considered interchangeable in clinical practice (Winer 
et al 2005).
The full deﬁ  nition of long-term safety proﬁ  les for AIs 
is related to the maturity of available safety data. The situa-
tion is presently improving with reports on anastrozole at 68 
months median follow-up and recent publications on letro-
zole and exemestane with, respectively, median follow-ups 
of 51 and 55 months. However, full safety data are required 
for all three agents over the full 5-year adjuvant treatment 
period before being able to fully determine their respective 
risk:beneﬁ  t ratios.
With this goal in mind, 2 global risk-beneﬁ  t indices 
were calculated for anastrozole in the ATAC trial, using 
the ‘completion of treatment’ analysis data (ATAC Trial-
ists’ Group 2006). The ﬁ  rst index is the validated Global 
Index of the Women’s Health Initiative (GI-WHI) based 
upon time to randomization to the earliest occurrence of 
breast cancer events, death, coronary heart disease, stroke, 
pulmonary embolism, endometrial cancer, colorectal can-
cer, and hip fracture. Results showed that patients treated 
with anastrozole had a lower incidence of events compared 
to those on tamoxifen (24% vs 27%, HR0.85, 95% CI: 
0.77–0.94, p = 0.0014). The second indice is the Global 
Index of Disease-Free Survival and Serious Adverse Events 
(GI-DFS-SAE) constructed on the following events: time to 
recurrence, death, or any serious adverse events observed in 
the ‘completion of treatment’ 68 months median follow-up 
analysis of the ATAC study. The Global Index showed 1453 
events (46%) for anastrozole and 1594 (51%) for tamoxi-
fen (HR0.88, 95% CI: 0.82–0.94, p = 0.0004). Cumulative 
occurrence of events over time conﬁ  rmed, for both indexes, 
a signiﬁ  cant difference in favor of anastrozole appearing 
early, highest during the ﬁ  rst 2 years of therapy and car-
ried over the full 5 years of treatment (ATAC Trialists’ 
Group 2006).
Updated data are needed from the BIG 1-98 with a full 5 
years exposure to letrozole in order to fully evaluate its risk-
beneﬁ  t ratio compared to tamoxifen in the adjuvant upfront 
endocrine therapy. While the duration of patient exposure 
to exemestane was limited to 2–3 years in the IES, it is 
difﬁ  cult to draw ﬁ  rm conclusions on the long term toxicity 
proﬁ  le of exemestane. In this regard, mature results from the Therapeutics and Clinical Risk Management 2008:4(1) 202
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presently closed adjuvant TEAM study, comparing 5 years 
of exemestane to 5 years of tamoxifen as upfront adjuvant 
endocrine therapy for postmenopausal women, are eagerly 
awaited.
Conclusions
Third-generation AIs are now part of the armamentarium 
of endocrine therapy for postmenopausal patients with 
hormone-sensitive breast cancer. AIs results are consis-
tently superior of those of tamoxifen. However, the best 
therapeutic strategies for AIs in adjuvant setting remain 
to be conﬁ  rmed, in particular in terms of the role of the 
sequential approach and the duration of therapy beyond 5 
years. While all three AIs have class adverse events either 
favorable (decreased incidence of hot ﬂ  ushes, gynecologic 
and thromboembolic side effects) or unfavorable (skeletal 
complications, arthralgia, musculoskeletal pain, sexual dys-
function), some variability between AIs has been reported 
in side effects such as lipid changes and cardiac events as 
well as gastrointestinal, urogenital, neurologic, and visual 
disturbances. All these safety data confirm that today 
AIs should not be considered interchangeable in clinical 
practice. First results of overall therapeutic index of AIs 
suggest superiority over tamoxifen with proven improved 
efﬁ  cacy and better toxicity proﬁ  le. Since there is no direct 
comparison between the three available AIs in adjuvant 
setting, the decision to use one speciﬁ  c AI should be based 
upon their respective efﬁ  cacy and toxicity proﬁ  les, maturity 
of data and availability of results within the chosen clinical 
strategies.
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